In vivo p53 response and immune reaction underlie highly effective low-dose radiotherapy in follicular lymphoma

Blood

Volumn 110, Issue 4, 2007, Pages 1116-1122

  Knoops, Laurent ^a,b   Haas, Rick ^a   De Kemp, Sanne ^a   Majoor, Donné ^a   Broeks, Annegien ^a   Eldering, Eric ^c   De Boer, Jan Paul ^a,d   Verheij, Marcel ^a   Van Ostrom, Conny ^a,d   De Vries, Annemieke ^a,d   Van't Veer, Laura ^a   De Jong, Daphne ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

APOPTOSIS; ARTICLE; CANCER RADIOTHERAPY; CELL CYCLE ARREST; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; FOLLICULAR LYMPHOMA; GENE EXPRESSION; HUMAN; IMMUNE RESPONSE; IMMUNOCHEMISTRY; IN VIVO STUDY; LOW ENERGY RADIATION; MICROARRAY ANALYSIS; PRIORITY JOURNAL;

EID: 34548040158     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2007-01-067579     Document Type: Article

References (30)

1. Hiddemann W, Buske C, Dreyling M, et al. Treatment strategies in follicular lymphomas: current status and future perspectives. J Clin Oncol. 2005;23:6394-6399.
2. Haas RL, Poortmans P, de Jong D, et al. High response rates and lasting remissions after lowdose involved field radiotherapy in indolent lymphomas. J Clin Oncol. 2003;21:2474-2480.
3. Girinsky T, Guillot-Vals D, Koscielny S, et al. A high and sustained response rate in refractory or relapsing low-grade lymphoma masses after low-dose radiation: analysis of predictive parameters of response to treatment. Int J Radiat Oncol Biol Phys. 2001;51:148-155.
4. Fei P, El Deiry WS. P53 and radiation responses. Oncogene. 2003;22:5774-5783.
5. Haas RL, de Jong D, Valdes Olmos RA, et al. In vivo imaging of radiation-induced apoptosis in follicular lymphoma patients. Int J Radiat Oncol Biol Phys. 2004;59:782-787.
6. Ogilvy S, Metcalf D, Print CG, et al. Constitutive Bcl-2 expression throughout the hematopoietic compartment affects multiple lineages and enhances progenitor cell survival. Proc Natl Acad Sci U S A. 1999;96:14943-14948.
7. Langenau DM, Jette C, Berghmans S, et al. Suppression of apoptosis by bcl-2 overexpression in lymphoid cells of transgenic zebrafish. Blood. 2005;105:3278-3285.
8. Haas RL, de Jong D, Valdes Olmos RA, et al. In vivo imaging of radiation-induced apoptosis in follicular lymphoma patients. Int J Radiat Oncol Biol Phys. 2004;59:782-787.
9. Yang YH, Dudoit S, Luu P, et al. Normalization for cDNA microarray data: a robust composite method addressing single and multiple slide systematic variation. Nucleic Acids Res. 2002;30:e15.
10. Hughes TR, Marton MJ, Jones AR, et al. Functional discovery via a compendium of expression profiles. Cell. 2000;102:109-126.
11. Yang YH, Dudoit S, Luu P, et al. Normalization for cDNA microarray data: a robust composite method addressing single and multiple slide systematic variation. Nucleic Acids Res. 2002;30:e15.
12. Sturn A, Quackenbush J, Trajanoski Z. Genesis: cluster analysis of microarray data. Bioinformatics. 2002;18:207-208.
13. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A. 2001;98:5116-5121.
14. Eldering E, Spek CA, Aberson HL, et al. Expression profiling via novel multiplex assay allows rapid assessment of gene regulation in defined signalling pathways. Nucleic Acids Res. 2003;31:e153.
15. Hartmann A, Schlake G, Zaak D, et al. Occurrence of chromosome 9 and p53 alterations in multifocal dysplasia and carcinoma in situ of human urinary bladder. Cancer Res. 2002;62:809-818.
16. Bakkar AA, Wallerand H, Radvanyi F, et al. FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder. Cancer Res. 2003;63:8108-8112.
17. Olivier M, Eeles R, Hollstein M, et al. The IARC TP53 database: new online mutation analysis and recommendations to users. Hum Mutat. 2002;19:607-614.
18. Mathe E, Olivier M, Kato S, et al. Predicting the transactivation activity of p53 missense mutants using a four-body potential score derived from Delaunay tessellations. Hum Mutat. 2006;27:163-172.
19. Kato S, Han SY, Liu W, et al. Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc Natl Acad Sci U S A. 2003;100:8424-8429.
20. Jeffers JR, Parganas E, Lee Y, et al. Puma is an essential mediator of p53-dependent and -independent apoptotic pathways. Cancer Cell. 2003;4:321-328.
21. Oda E, Ohki R, Murasawa H, et al. Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science. 2000;288:1053-1058.
22. Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell. 1995;80:293-299.
23. Taylor PR, Carugati A, Fadok VA, et al. A hierarchical role for classical pathway complement proteins in the clearance of apoptotic cells in vivo. J Exp Med. 2000;192:359-366.
24. Grainger DJ, Reckless J, McKilligin E. Apolipoprotein E modulates clearance of apoptotic bodies in vitro and in vivo, resulting in a systemic proinflammatory state in apolipoprotein E-deficient mice. J Immunol. 2004;173:6366-6375.
25. Fei P, El Deiry WS. P53 and radiation responses. Oncogene. 2003;22:5774-5783.
26. Amundson SA, Grace MB, McLeland CB, et al. Human in vivo radiation-induced biomarkers: gene expression changes in radiotherapy patients. Cancer Res. 2004;64:6368-6371.
27. Rosenwald A, Chuang EY, Davis RE, et al. Fludarabine treatment of patients with chronic lymphocytic leukemia induces a p53-dependent gene expression response. Blood. 2004;104:1428-1434.
28. de Jong D. Molecular pathogenesis of follicular lymphoma: a cross talk of genetic and immunologic factors. J Clin Oncol. 2005;23:6358-6363.
29. Haas RL, de Jong D, Valdes Olmos RA, et al. In vivo imaging of radiation-induced apoptosis in follicular lymphoma patients. Int J Radiat Oncol Biol Phys. 2004;59:782-787.
30. Connors JM. Radioimmunotherapy: hot new treatment for lymphoma. N Engl J Med. 2005;352:496-498.